Evidence Europe 2017. London, UK - February 22-23, 2017

Area of Science:

• Healthcare economics
• Pharmaceutical policy
• Evidence-based medicine

Background:

• The pharmaceutical industry faces significant volatility due to evolving political landscapes in the U.S. and Europe.
• U.S. policy changes, including potential Affordable Care Act repeal and drug price regulations, introduce market uncertainty.
• European regulatory and trade uncertainties stemming from Brexit impact the pharmaceutical sector.

Framework:

• The Evidence Europe meeting convened experts to discuss the role of evidence in defining and communicating healthcare value.
• Focus on real-world evidence (RWE) as a critical tool for navigating industry challenges.
• Exploration of strategies to address the complexities of value assessment in a dynamic environment.

Implementation:

• Presentations and panel briefings shared insights on current industry challenges.
• Roundtable discussions facilitated debate on practical approaches to value demonstration.
• The conference provided a platform for stakeholders to share knowledge and best practices.

Implications:

• Understanding and leveraging real-world evidence is crucial for pharmaceutical companies.
• Adapting strategies to political and regulatory changes is essential for market access.
• The discussions highlighted the need for robust value communication in healthcare.